Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...

Time to failure improved by 5 months, but questions raised about endpoint, applicability t ...

A meta-analysis found that patients with early and intermediate-stage hepatocellular carcinoma who received external beam radiation therapy (EBRT) demonstrated better local control and ...

The efficacy of transarterial techniques can be assessed in terms of imaging response (CT scan), biologic response (AFP), degree of tumor necrosis, patient survival or quality of life. The most ...

A new study of liver cancer shows three ways to reduce the risk in the majority of cases. We learn more about what they are and what else the study found. The third leading cause of cancer death is ...

Proton pump inhibitors and clinical outcomes in hepatocellular carcinoma patients: A propensity score–matched analysis from a global federated dataset. The efficacy and safety of donafenib combined ...